A Randomized, Open Label, Four Period, Four Sequence, Single Dose, Crossover Study to Evaluate Relative Bioavailability of K0706 24 mg Tablet Formulation Relative to 24 mg Capsule Formulation Under Fasted Conditions and to Evaluate the Food Effect for Tablet Formulation in Healthy Subjects
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Vodobatinib (Primary)
- Indications Chronic myeloid leukaemia; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Sun Pharma Advanced Research Company
Most Recent Events
- 26 Jan 2018 Status changed from not yet recruiting to completed.
- 25 Oct 2017 New trial record